WAVE Life Sciences Aktie

WAVE Life Sciences ab 0 Euro bei Finanzen invest ordern (zzgl. Spreads)

WKN DE: A1436W / ISIN: SG9999014716

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
<
Aktion
Portfolio
Watchlist
>
01.10.2026 16:44:32

Wave Gains FDA Support For WVE-006 Registrational Pathway In AATD

(RTTNews) - On Thursday, Wave Life Sciences (WVE) said it reached alignment with the FDA on key aspects of the registrational pathway for WVE-006, an investigational RNA editing therapy for alpha-1 antitrypsin deficiency (AATD).

WVE-006 is a GalNAc-conjugated, subcutaneously delivered RNA editing oligonucleotide designed to correct the RNA mutation associated with the Pi*ZZ genotype, potentially increasing healthy M-AAT and reducing mutant Z-AAT accumulation in the liver.

Wave plans a single two-year registrational trial to support potential full approval, with a one-year interim analysis that could support accelerated approval based on AATD biomarkers. The FDA also supports use of Wave's current LC-MS assay to measure M-AAT and Z-AAT protein.

WVE-006 is currently being evaluated in the Phase 1b/2a RestorAATion-2 trial. Wave expects to report data from the 600 mg monthly multidose cohort in the fourth quarter of 2026. The company said WVE-006 continues to be generally safe and well tolerated, with no liver toxicities reported.

Currently, WVE is trading at $3.95, up 6.89%.

Nachrichten zu WAVE Life Sciences Ltd

mehr Nachrichten
Keine Nachrichten verfügbar.

Analysen zu WAVE Life Sciences Ltd

mehr Analysen
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!